CoChat

Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation

Open access
Rymer, Jennifer A., Mues, Katherine E., Monda, Keri L., Bratton, Emily W., Wirtz, Heidi S., Okerson, Ted, Overman, Robert A., Brookhart, M. Alan, Muntner, Paul, Wang, Tracy Y. · 2020 · Journal of the American Heart Association
Cited by 23

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background: Proprotein convertase subtilisin/kexin type 9 inhibitors ( PCSK 9i) are used to reduce low‐density lipoprotein ( LDL ) cholesterol. PCSK 9i use after initiation, as well as persistence with or alterations to other LDL ‐lowering therapy after PCSK 9i initiation, is not well understood. Methods and Results: We conducted a retrospective study of alirocumab or evolocumab ( PCSK 9i) new users from July 2015 to December 2017 in the MarketScan Early View database of US commercial insurance beneficiaries. We determined the prevalence of PCSK 9i interruption (≥30‐day gap in supply) and LDL ‐lowering therapy use in the year after PCSK 9i initiation. The average age of 6151 patients initiating PCSK 9i therapy was 63 years, 44.4% were women, and 76.8% had atherosclerotic cardiovascular disease. Overall, 52.2% (95% CI , 50.8%–53.7%) of patients had an interruption in PCSK 9i therapy in the first year after treatment initiation and 62.5% remained on PCSK 9i therapy at 1‐year postinitiation. Also, 27.7% of patients were taking a statin at the time of PCSK 9i initiation, with only 22.4% on statin therapy at 1 year after PCSK 9i initiation. Ezetimibe use decreased from 20.9% at the time of PCSK 9i initiation to 12.0% a year later. By 1 year after PCSK 9i initiation, 44.0% of patients had experienced an interruption in all LDL ‐lowering therapies, and 26.6% were no longer on any LDL ‐lowering therapies. Conclusions: After PCSK 9i initiation, statins were often discontinued, whereas more than half of patients experienced an interruption in PCSK 9i therapy. These results suggest that many new PCSK 9i users may remain at high risk for cardiovascular events because of interruptions in LDL ‐lowering therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/jaha.119.014347

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 23

Metadata

Authors
Rymer, J. A., Mues, K. E., Monda, K. L., Bratton, E. W., Wirtz, H. S., Okerson, T., Overman, R. A., Brookhart, M. A., Muntner, P., & Wang, T. Y.
Venue
Journal of the American Heart Association
Published
2020-05-05
Volume
9
Issue
9
Pages
e014347-e014347
ISSN
2047-9980 (ISSN-L)
OpenAlex
W3017798522
Cited by
23
References
6
FWCI
2.88
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation. https://app.cochat.ai/papers/10.1161/jaha.119.014347
The paper
Rymer, J. A., Mues, K. E., Monda, K. L., Bratton, E. W., Wirtz, H. S., Okerson, T., Overman, R. A., Brookhart, M. A., Muntner, P., & Wang, T. Y. (2020). Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation. Journal of the American Heart Association. https://doi.org/10.1161/jaha.119.014347

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.